BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy

MT Newswires Live12-13

BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a marketing authorization for the drug to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy, the regulator said Friday.

The CHMP cited a pivotal study that showed treatment with acoramidis, or Beyonttra, reduced cardiovascular hospitalizations over a 30-month period, according to the regulator.

BridgeBio said it expects a final decision from the European Commission "in the coming months" and plans to launch the drug in Europe in H1 2025.

Acoramidis was approved by the US Food and Drug Administration last month as Attruby, BridgeBio added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491205203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491205203","market":"fut","top_or_hot":-1,"title":"BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy","media":"MT Newswires Live","content":"<html><body><p> BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a marketing authorization for the drug to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy, the regulator said Friday.</p><p>The CHMP cited a pivotal study that showed treatment with acoramidis, or Beyonttra, reduced cardiovascular hospitalizations over a 30-month period, according to the regulator.</p><p>BridgeBio said it expects a final decision from the European Commission \"in the coming months\" and plans to launch the drug in Europe in H1 2025.</p><p>Acoramidis was approved by the US Food and Drug Administration last month as Attruby, BridgeBio added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 21:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2491205203","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491205203","pubTimestamp":1734097078,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a marketin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BBIO":"BridgeBio Pharma, Inc.","BK4156":"煤与消费用燃料","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"BridgeBio的Acoramidis被欧盟小组推荐用于甲状腺素运载蛋白淀粉样心肌病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BridgeBio Pharma's (BBIO) acoramidis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, which recommended granting a marketing authorization for the drug to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy, the regulator said Friday.The CHMP cited a pivotal study that showed treatment with acoramidis, or Beyonttra, reduced cardiovascular hospitalizations over a 30-month period, according to the regulator.BridgeBio said it expects a final decision from the European Commission \"in the coming months\" and plans to launch the drug in Europe in H1 2025.Acoramidis was approved by the US Food and Drug Administration last month as Attruby, BridgeBio added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491205203"}